PMP22 transcripts were strongly increased in rodent models and patients, without correlation with neuropathy progression.18,19 Multiplexed immune-assay identified elevated plasma TMPRSS5 in CMT1A patients (n = 47), without correlation with disease severity.20 It has recently been proposed that a set of micro RNAs (miR-206, miR-133a and miR-223-3p) are also candidate biomarkers for CMT1A, as they may reflect Schwann cell processes that underlie the pathogenesis of the disease. The gene discussed is PMP22; the disease is Charcot-Marie-Tooth disease type 1A.